Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2026—City of Hope is implementing Quest Diagnostics’ Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial patients with solid tumor cancers to help guide disease management for breast, colorectal, ovarian, and prostate cancer.
May 2026—Clinical Lab 2.0, an initiative of Project Santa Fe Foundation, is partnering with Life Data Lab, developer of Vivica LabReports, a laboratory platform that enables clinical labs to identify potential gaps in patient care (per provider request).
May 2026—Labcorp launched the Labcorp Fentanyl Urine Visual test for the assessment of fentanyl exposure. The test detects norfentanyl, which can remain present in urine up to 48 hours after initial exposure.
May 2026—Omnia Inventa Medical has introduced the Lymph Node Locator 300, an FDA class I, 510(k)-exempt device designed to standardize lymph node retrieval from fatty tissue in oncologic specimens.
May 2026—The Food and Drug Administration granted 510(k) clearance to Roche’s Cobas c 703 and Cobas ISE Neo analytical units.
April 2026—The Food and Drug Administration has granted breakthrough device designation to the NG-Test Candida auris and NG-Test Acineto-5 assays, which are developed and manufactured in France by NG Biotech and distributed exclusively in the United States by Hardy Diagnostics.
April 2026—Leica Biosystems launched the Leica CM1950 Cryostat with DualEcoTec cooling system for in vitro diagnostic use.
April 2026—Quest Diagnostics has launched Quest Flow Cytometry MRD for Myeloma, a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease in patients who have myeloma.
April 2026—The FDA has granted breakthrough device designation to MeMed’s BV Flex, a blood test designed to distinguish between bacterial and viral infections based on the body’s immune response.
April 2026—Devyser has entered into a strategic agreement with Illumina in which Devyser will offer selected Illumina sequencing instruments with Devyser’s reagent solutions.
